DNA methylation as a biomarker in cancer

Shinichi Fukushige, Akira Horii

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

DNA methylation alteration is one of the most prominent epigenetic changes in cancer. Because DNA originated fromcancer cells is a stablemolecule that is easily detectable in clinical specimens such as blood, sputum, urine, and stool, DNA methylation alterations in tumorigeneses have become one of the promising candidate biomarkers for early detection, prognosis, therapeutic response prediction, and recurrence monitoring in cancer patients. Recent development of technologieshas allowed global genome-wide DNA methylation analysis in normal as well as in cancer cells and has provided extensive information for candidate biomarkers. Herein we summarize the features of DNA methylation in cancer, their suitability as DNA methylation biomarkers in comparison with others, and their status in applications of DNA methylation biomarkers in cancer. The research field of DNA methylation biomarking is evolving rapidly with promising results that have the potential to confer enormous benefits for cancer patients in the future.

Original languageEnglish
Title of host publicationBiomarkers in Disease
Subtitle of host publicationMethods, Discoveries and Applications: Biomarkers in Cancer
PublisherSpringer Netherlands
Pages107-133
Number of pages27
ISBN (Electronic)9789400776814
ISBN (Print)9789400776807
DOIs
Publication statusPublished - 2015 Jan 1

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'DNA methylation as a biomarker in cancer'. Together they form a unique fingerprint.

Cite this